The Study of Oral Findings, Oxidative Stress and Antioxidant Vitamin E in Serum and Saliva of Crohn's Patients on Azathioprine Monotherapy and those on Combination of Anti-TNF-α Plus Azathioprine
Main Article Content
Abstract
Subjects, Materials, and Methods: Seventy-five subjects were incorporated in this study; fifty subjects presented with moderate to severe CD that were subdivided into two subgroups treated with different therapeutic modalities( Azathioprine monotherapy and Combination of anti TNF-α biological agent (Infliximab) plus Azathioprine), while other twenty-five were age and gender matched healthy control subjects. Body mass index (BMI) of all participants was determined by weight (kg)\ high (m2). Oral cavity of each patient was examined for the presence of oral manifestations. Blood and saliva samples were gained from each subject enrolled in this study and salivary flow rate (ml\min) was measured for those participants, then these samples were centrifuged and the supernatants frizzed for subsequent oxidative stress and antioxidants biomarkers assessment.
Results: The means of BMI and salivary flow rate were significantly higher in combination treated group than Azathioprine treated group. Fungal infection was the main oral findings that observed among Crohn's patients on combination therapy compared with those on Azathioprine monotherapy. Assessment of oxidative stress and antioxidant activity revealed that the means of serum and saliva Malondialdehyde (MDA) were highly significantly higher in Azathioprine treated group than combination treated group, while Vitamin E (VE) level showed significant reduction in Azathioprine Crohn's group as compared to combination treated group. Significant negative linear correlation was found between MDA level in serum and saliva with duration of treatment, while highly significant positive correlation was detected between VE levels and duration of treatment.
Conclusions: Oxidative stress was increased with reduced antioxidant level in both groups of Crohn's patients. Treatment with Combination therapy approved to be effective in controlling oxidative tissue damage and enhanced antioxidants system in Crohn's patients better than Azathioprine monotherapy. Fungal infection was the most predominant oral manifestations among Crohn's patients on combination therapy as a result of concomitant immunosuppressive effect that accounted for reduced immune response to opportunistic infections.
Downloads
Article Details
Licenses and Copyright
The following policy applies in The Journal of Baghdad College of Dentistry (JBCD):
# JBCD applies the Creative Commons Attribution (CC BY) license to articles and other works we publish. If you submit your paper for publication by JBCD, you agree to have the CC BY license applied to your work. Under this Open Access license, you as the author agree that anyone can reuse your article in whole or part for any purpose, for free, even for commercial purposes. Anyone may copy, distribute, or reuse the content as long as the author and original source are properly cited. This facilitates freedom in re-use and also ensures that JBCD content can be mined without barriers for the needs of research.
# If your manuscript contains content such as photos, images, figures, tables, audio files, videos, etc., that you or your co-authors do not own, we will require you to provide us with proof that the owner of that content (a) has given you written permission to use it, and (b) has approved of the CC BY license being applied to their content. We provide a form you can use to ask for and obtain permission from the owner. If you do not have owner permission, we will ask you to remove that content and/or replace it with other content that you own or have such permission to use.Don't assume that you can use any content you find on the Internet, or that the content is fair game just because it isn't clear who the owner is or what license applies.
# Many authors assume that if they previously published a paper through another publisher, they own the rights to that content and they can freely use that content in their paper, but that’s not necessarily the case, it depends on the license that covers the other paper. Some publishers allow free and unrestricted re-use of article content they own, such as under the CC BY license. Other publishers use licenses that allow re-use only if the same license is applied by the person or publisher re-using the content. If the paper was published under a CC BY license or another license that allows free and unrestricted use, you may use the content in your JBCD paper provided that you give proper attribution, as explained above.If the content was published under a more restrictive license, you must ascertain what rights you have under that license. At a minimum, review the license to make sure you can use the content. Contact that JBCD if you have any questions about the license. If the license does not permit you to use the content in a paper that will be covered by an unrestricted license, you must obtain written permission from the publisher to use the content in your JBCD paper. Please do not include any content in your JBCD paper which you do not have rights to use, and always give proper attribution.
# If any relevant accompanying data is submitted to repositories with stated licensing policies, the policies should not be more restrictive than CC BY.
# JBCD reserves the right to remove any photos, captures, images, figures, tables, illustrations, audio and video files, and the like, from any paper, whether before or after publication, if we have reason to believe that the content was included in your paper without permission from the owner of the content.